Cornerstone Pharmaceuticals includes Mary Crowley Research Centers in CPI-613 clinical trials

Cornerstone Pharmaceuticals, Inc. today announced the addition of Mary Crowley Cancer Research Centers to its roster of sites for its ongoing Phase I/II clinical trials of its first-in-class anti-cancer agent, CPI-613.  Cornerstone is a leader in the discovery and development of cancer therapies that capitalize upon and disrupt the unique metabolic processes of cancer cells.

"As one of the national pioneers in early phase clinical trials, the Mary Crowley Cancer Research Center in Dallas is an ideal site addition to our ongoing clinical evaluation of CPI-613 in cancer patients," said Dr. Robert Shorr, Chief Executive Officer of Cornerstone Pharmaceuticals. "Our trials will benefit greatly from the center's vast expertise in cancer therapies research. "

The trials, which are currently enrolling patients suffering from multiple types of cancer, are to be led by Neil Nathan Senzer, M.D., Scientific Director of the Mary Crowley Research Centers. The two separate trials evaluate CPI-613: the first as a single agent and the second combining CPI-613 with gemcitabine.

"Our ongoing objective at Mary Crowley Cancer Research Centers is to improve patient outcomes by providing novel agents available only through clinical trials in addition to standard-of-care therapies," said Neil Nathan Senzer, M.D. "With that objective in mind, we are excited to support the advancement of Cornerstone's unique anti-cancer drug CPI-613 by serving as a site for its clinical evaluation."